The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a significant boost to Pfizer’s lung cancer drug, Vizimpro (dacomitinib), recommending its approval as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This recommendation specifically targets patients with epidermal growth factor receptor […]
Texas-based biopharmaceutical company Genprex has unveiled positive interim data from an ongoing phase II clinical trial, NCT01455389, for its lung cancer drug candidate, Oncoprex. Conducted at The University of Texas MD Anderson Cancer Center, the trial focuses on the investigational immunogene therapy drug in combination with the tyrosine kinase inhibitor erlotinib (Tarceva), targeting patients with […]
